The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 361:1707-1708 October 22, 2009 Number 17
NextNext

Inhibition of Poly(ADP-Ribose) Polymerase in BRCA Mutation Carriers

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Fong, P. C.
-PubMed Citation
To the Editor: Fong et al. (July 9 issue),1 who used the poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor olaparib to treat tumors in patients who were carriers of BRCA mutations, state that two deaths "were deemed unlikely to be related to olaparib." However, it is possible that the second patient died of impaired immunity induced by olaparib. Chemotactic cytokines, or chemokines, mediate the recruitment of inflammatory cells to inflamed sites. TRPM2, a plasma membrane Ca2+-permeable channel, controls chemokine production induced by reactive oxygen species in monocytes.2 TRPM2 channel opening in response to oxidative stress depends on activation of PARP.3,4 . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.